🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The ODAC on 3/15/24 on cilta-cel and ide-cel was like a plenary or late breaking abstracts session at ASH along with elements of America’s Got Talent. Lots of data being presented, discussion and analysis, and voting too!

Thanks Rahul Banerjee, MD, FACP! We're looking forward to presenting the poster at ASCO. Excellent outcomes when using daratumumab combinations upfront for patients hospitalized with acute kidney injury (including on dialysis) from myeloma. And this is without plasmapheresis.

Improving outcomes with anti-BCMA bispecific antibodies with attention to infection | Blood Cancer Journal Andrew Yee, MD nature.com/articles/s4140…

An ATLAS to map MRD with peripheral blood: a nice editorial on mass spec in MM #mmsm #bmtsm Andrew Yee, MD ashpublications.org/blood/article/…

Joining in for #ASHaiku #ASH24 In San Diego, friends gather, sharing new hope for myeloma (with some assistance from ChatGPT 😀)

This was a very practical poster at #ASH24, looking at prolonged dosing intervals of teclistamab, which is very relevant as dosing of tec (and other bispecific antibodies) moves to q4 week (or even longer intervals). New recommendation: if dosing interval ≤62 days, no need to

Subcutaneous isatuximab is on the horizon! Press release on phase 3 IRAKLIA study shows s.c. similar to i.v. (as would be expected). Hopefully this will enable approval and availability of s.c. isatuximab soon! sanofi.com/en/media-room/…

Super useful table by Ben Derman for benchmarking depth of response with induction therapy, especially as trials in newly diagnosed MM are starting to include anti-BCMA therapies which may take things further.